The TPR-METoncogenic rearrangement was originally observed in an in vitro transformed human osteosarcoma cell line. Recently, we detected the expression of this rearrangement at very low levels in several cell lines derived from human tumors of nonhematopoietic origin using a highly sensitive method based on polymerase chain reaction amplification of the transcript. We report here the results of analysis of TPR-MET expression in cell lines derived from human gastric tumors and 22 biopsy samples of human gastric mucosa showing cancer or precursor lesions. The rearranged RNA was expressed in all four cell lines as well as in biopsy samples from 12 of the 22 patients.'Overexpression of TPR-MET RNA in superficial gastritis lesions' with hyperplasia of glandular neck cells suggests the possible involvement of this oncogene at an early stage of gastric tumorigenesis. Analysis of gastric biopsy samples for RAS gene mutations showed base substitutions occurring in the codon 12 region of Ki-and Ha-RAS genes in four cases, including two precursor lesions.
The TPR-MET oncogenic rearrangement was first observed in a human osteosarcoma cell line (HOS) transformed in vitro by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) (1, 2) . The rearrangement involved the fusion of a TPR (translocated promoter region) locus present on chromosome 1 to the 5' region of MET gene sequences located on chromosome 7 (3, 4) . The oncogenic TPR-MET RNA is a 5.0-kilobase (kb) hybrid transcript encoding a 65-kDa fusion protein (3, 4) . To permit detection of the rearranged RNA in tumor tissues, we developed a sensitive analytical procedure in which cDNA generated from the fused transcript was used as a template for PCR amplification of the breakpoint region of the TPR-MET gene. Using this method, we found TPR-MET RNA to be expressed at low levels by cell lines derived from several human tumors of nonhematopoietic origin (5) .' Amplification and overexpression ofthe c-METgene was recently observed in a human gastric tumor cell line, (6) , suggesting a possible role of the MET oncogene in gastric tumorigenesis.
The human model of gastric carcinogenesis (7) shares certain features with colorectal cancer, with respect to the progress of its development. Epidemiological and laboratory data have shown the disease to progress through at least six stages, in which morphological features and biochemical markers of differentiation define the progression to malignancy: superficial gastritis (SG); chronic atrophic gastritis (CAG); intestinal metaplasia of the small intestinal type followed by the colonic type (IM-CT); dysplasia (DYS); and carcinoma (Ca). The progression from normal to neoplastic cells appears to take place over a period of many years, under the combined influence of modulating forces of different types. These include carcinogens (e.g., N-nitroso compounds), irritants (especially salt), bacterial infection (Helicobacter pylorO, protective agents (micronutrients and nonnutrient factors), and genetic susceptibility. The multitude of phenotypic changes seen in the precancerous phases of the disease and their apparently gradual occurrence suggest a complex interplay of modulating factors and genetic changes in cells ofthe gastric epithelium. Genetic alterations in gastric carcinogenesis have not been extensively studied, in contrast to the molecular genetics of colorectal cancer, a disease that also develops through a series of morphologically characteristic stages, which have been the subject of intense investigation. Current evidence supports a model of colorectal cancer in which events required for tumor development often include the mutational activation of an oncogene (the Ki-RAS gene), DNA hypomethylation, and loss of the tumor suppressor genes p53 and DCC (8).
As noted above, the TPR-MET rearrangement was originally identified'in cells transformed by MNNG, a potent mutagen and' carcinogen that induces gastric tumors in experimental animals (9) . On the basis of evidence suggesting involvement of environmental carcinogens as risk factors for human gastric cancer, it was of interest to determine whether genetic alterations take place during gastric cancer development that could plausibly be related to carcinogen exposure and also relate to those found in colorectal cancer. To study the possible involvement of the TPR-MET oncogenic rearrangement in human gastric tumorigenesis, we analyzed four cell lines derived from human gastric tumors as well as biopsy samples of human gastric mucosa containing histopathologic lesions characteristic of various stages in the development of gastric cancer. We found TPR-MET RNA to be expressed frequently in gastric Ca as well as preneoplastic tissues. Concurrent analysis of these tissues for RAS gene mutations also demonstrated base substitution mutations in the exon 1 region of Ki-RAS and Ha-RAS genes in some cases.
MATERIALS AND METHODS
Osteosarcoma cell lines HOS 6374 (passage 62) and MNNG-HOS were grown as described (5) . Gastric cell lines MKN1, MKN28, MKN45, and SCH were grown in RPMI 1640 medium containing 10o fetal bovine serum (10) . The MKN1 line was established from an adenosquamous Ca; the MKN28 line was from a well-differentiated, tubular adenocarcinoma; the MKN45 line was from a poorly differentiated adenocarcinoma; and the SCH line was from a choriocarcinoma (10 About 10-15 ,ul of PCR aliquot was digested overnight by BstNI enzyme under the conditions specified by the manufacturer and the products were separated on an 8% polyacrylamide gel. The mutant DNA fragment was recovered from the gel and directly sequenced using a 32P-end-labeled internal primer, [B, using Sequenase enzyme as described above. In cases in which an adequate amount ofDNA was not available for direct sequencing, the 143-bp DNA was further reamplified using primers, KHE5' and f3, to produce an 87-bp fragment and used for sequence analysis.
Similarly, presence of a codon 13 aspartic acid mutation was determined by Hph I analysis. The wild-type allele did not carry any Hph I recognition site, whereas substitution by an adenosine residue at position 2 of codon 13 created a new Hph I site, giving rise to two fragments (118 bp and 43 bp, respectively) upon Hph I digestion.
For Ha-RAS, HA12E5' (24-mer), 5'-GGAATTCAT-GACGGAATATAAGCT-3'; HA12B3' (24-mer), 5'-GGATCCACAAAATGGTTCCGGATC-3'; and Hp (20- including the one sample expressing TPR-MET RNA, were negative for HLO infection.
As shown in Fig. 2 A and B , variable levels of expression of TPR-MET RNA were observed in some biopsy samples representing each stage of progression from SG to Ca. Interestingly, the highest level of expression was observed in one sample at the earliest SG stage ( Fig. 2A; case 1) . The TPR-MET rearrangement was expressed in two of four biopsy samples with SG lesions. Comparatively low levels of expression of the rearranged RNA were observed in later stages, with the exception of one sample containing gastric Ca ( Fig. 2B; case 1) . The SG tissue with a high level of TPR-MET RNA showed only mild inflammation, but it also showed hyperplasia of the glandular necks, a sign of recent injury to the gastric mucosa followed by gland repair by means of hyperproliferation of neck cells (Fig. 3A) . Neither case of SG showing TPR-MET expression had evidence of infection with HLO.
One of two Ca studied expressed relatively high levels of TPR-MET RNA (see Fig. 2B and Table 1 ). Histologically, this was a well-differentiated adenocarcinoma of the intestinal or "expansive" type (see Fig. 3B ). This is the predominating type of gastric Ca found in high-risk populations and Fig. 3C ). Among samples from 12 patients with GAG, 7 expressed TPR-MET RNA (see Fig. 2 27 (17) gastric tumors, respectively. However, individual gastric tumors and cancer cell lines containing mutated Ha-RAS, Ki-RAS, or N-RAS alleles have been described (14, (18) (19) (20) (21) . The reasons for these discrepancies are not known but may in part be attributable to use of analytical methods with differing limits of detection and analysis of tumors at different stages of development and from several population groups, therefore possibly reflecting different etiologic agents.
In addition to mutational activation, overexpression of the normal RAS gene product (p21) has been shown to cause cell transformation. Several previous investigations have dealt with the possible role of enhanced oncogene expression in gastric carcinogenesis, but, as in the case of RAS mutations, the evidence currently available on this point is both fragmentary and limited in amount. Overexpression of RAS oncogene p21 protein in advanced gastric tumors has been reported by several investigators (16, 22, 23) . Enhanced p21 expression was found in nearly all advanced adenocarcinomas, in which it was also associated with invasiveness, metastasis, and poor prognosis. Recently, overexpression was also found in early Ca as well as in the dysplastic and/or metaplastic mucosal alterations accompanying intestinal type of gastric cancer (24) . Overexpression of the c-MYC gene product (p62) in advanced, but not early, gastric adenocarcinomas has also been reported (25) .
Gene transfer experiments have resulted in the identification of a transforming gene, HST, in human stomach cancers (26, 27) . This sequence was shown to be closely related to the v-RAF oncogene of the murine transforming retrovirus 3611-MSV. The transforming sequences were found at a frequency of 3/58 tumors in the initial study, but no further information is available concerning this gene or its role in gastric carcinogenesis.
Limited information is available regarding the precise role of the various known modulating factors and genetic changes involved in the progression of gastric carcinogenesis. The most common precursor of gastritis is the multifocal atrophic gastritis (MAG) complex, in which gland loss (atrophy) is followed by the expression of abnormal phenotypes resembling either small intestinal epithelium (small intestinal metaplasia or IM-SIT) or colonic epithelium (or IM-CT). In this setting, dysplastic changes take place that may eventually lead to invasive Ca. In high gastric cancer risk areas, gastric peptic ulcer is more frequent than duodenal ulcer. Duodenal ulcer is usually accompanied by DAG, which is not considered as a cancer precursor and in which gastric atrophy (gland loss) is not prominent. Recently, H. pylon has been recognized as a cause of chronic gastritis: it appears to play a dominant role in DAG and an adjuvant role in MAG (28) . HLO infection was severe in the two cases of DAG studied (Table 1) , which could be interpreted as lending some support to the hypothesis that H. pylon may play a role in the gastric precancerous process (28, 29) . These tissues also expressed TPR-MET RNA. However, the small number of samples analyzed does not establish a direct correlation between TPR-METexpression and H. pylon infection. In six patients, HLO was present in the absence of TPR-MET rearrangement, whereas TPR-METRNA was expressed in the absence of infection in three cases studied, including the SG (case 1) and Ca (case 1) tissues showing elevated expression of TPR-MET RNA.
The expression of the TPR-MET gene at the early stage of SG together with high expression in one of two cases examined suggest a possible functional role of this oncogene during the initial stages of gastric carcinogenesis. One of the early morphological changes observed in the pathogenesis is inflammation followed by atrophy or gland loss involving cell loss and regenerative hyperplasia. The TPR-MET gene may therefore be expressed in the early stages of gastric tumorigenesis as a consequence of the inflammatory response. Several factors, including irritants and micronutrient deficiency, may also play roles at this stage of the disease. The TPR-MET RNA expression continued through the later stages of the tumorigenesis process, including CAG, IM, and Ca. It is possible that endogenous mutagens such as N-nitroso compounds may cause cellular damage in the stomach epithelium contributing to the gradual progression of atrophic cells to cancer cells. Nitric oxide required for the synthesis Medical Sciences: Soman et al. of these nitroso compounds is often produced in the gastric cavity of patients as well as by macrophages participating in the inflammatory process (7). Our finding that the TPR-MET RNA is expressed in a majority of tissues analyzed shows that the TPR-MET oncogenic rearrangement is frequently associated with human gastric carcinogenesis and may constitute one genetic alteration associated with the progression of gastric epithelial cells to malignancy.
The MET protooncogene is a member of the protein tyrosine kinase growth factor receptor gene family. Activation of MET oncogene was shown to involve a chromosome translocation event, giving rise to the rearranged TPR-MET gene (3, 4) . Other investigators have reported a similar rearrangement mechanism leading to activation ofBCR-ABL in the Philadelphia chromosome translocation in chronic myeloid leukemia (30) (31) (32) (33) and the TRK gene (34) . Similar to MET, TRK protooncogene also codes for a growth factor receptor associated with protein tyrosine kinase activity. Another oncogene, PTC, associated with papillary thyroid Ca and showing rearrangement of H4 and the RET protooncogene sequences, also is a member of the same family (35) (36) (37) (38) . In both cases, the breakpoint occurred within the intron region and did not interfere with the reading frame of the downstream oncogene domains of MET and RAF. Involvement of a single 5' TPR domain in the activation of MET and RAF genes is suggestive of a putative role of the TPR gene in activation events. Recently, pulsed-field gel electrophoresis analysis of the chemically transformed human cell line MNNG-HOS showed that the TPR-METrearrangement may have occurred as a result of an insertion of at least 500 kbp of a portion of chromosome 1 carrying the TPR domain into the MET locus (39) . As noted by King et al. (38) , TPR DNA may have a high propensity to translocate into various genes and thereby disrupt their normal regulation. Some of the common features of growth control genes are that they often contain a heptad leucine repeat motif or leucine zipper domain required for protein dimerization and that their products are phosphorylated and involved in signal transduction events. It is interesting to note that the TPR domain involved in the activation of MET and RAF genes shares structural homology with the DNA binding leucine zipper motif of the protooncogene products of FOS and JUN, the cyclic AMP-response element binding protein, and the intermediate filament protein, vimentin (40) .
Two of 18 gastric samples analyzed showed base substitutions in the codon 12 region of the Ki-RAS gene and both of these mutations corresponded to activating mutations often associated with human neoplastic tissue. Two other samples showed cryptic mutations in the codon 12 region of the Ha-RAS gene. Whether such mutations are associated with changes in RAS expression needs to be investigated, inasmuch as mutational activation and overexpression of RAS gene products have been reported to occur in gastric tumors. Although we found that RAS gene mutations were present in some gastric tumors and precursor lesions, the frequency of these changes was substantially lower than that reported to be involved in colorectal carcinogenesis.
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